Today,
THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO
Summary of the Rights Issue
- Upon full subscription in the Rights Issue,
SciBase will receive issue proceeds of approximatelySEK 15 million before deduction of transaction costs. -
For each share held in the Company on the record date,
19 April 2024 , the holder received one (1) unit right. Ten (10) unit rights entitle the holder to subscribe for three (3) units. One (1) unit consists of one (1) new share and five (5) warrants of series TO 2. -
The subscription price is set to
SEK 0.42 per unit, corresponding toSEK 0.42 per share. The warrants of series TO 2 are issued free of charge. -
If the Rights Issue is fully subscribed and upon full exercise of warrants of series TO 2, the Company is expected to raise up to an additional amount of approximately
SEK 75 million , before deduction of transaction costs. -
The shareholder
Morningside Group AB and Members of the Board of Directors and management have undertaken to subscribe for units representing approximately 16.6 percent of the Rights Issue. The subscription commitments are not secured through bank guarantees, restricted funds, pledged assets or similar arrangements. -
The record date for the Rights Issue was
19 April 2024 and the subscription period in the Rights Issue is from and including23 April 2024 until and including7 May 2024 . -
Warrants of series TO 2 can be exercised for subscription of shares to a subscription price of
SEK 0.42 per share from and including3 April 2029 until and including17 April 2029 .
Prospectus
Complete information regarding the Rights Issue and information about the Company can be found in the prospectus published on
Timetable for the Rights Issue
Trading in unit rights | |
Subscription period | |
Trading in BTU | |
Around | Announcement of the outcome of the Rights Issue |
Subscription period for warrants of series TO 2 |
Advisors
For additional information, please contact:
Certified Advisor (CA)
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at
The Company has been on the Nasdaq First North Growth Market exchange since
Important information
Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in
This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of units in
This press release does not constitute an offer or solicitation to buy or subscribe for securities in
Forward-looking statements
This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as "believes," "expects," "anticipates," "intends," "estimates," "will," "may," "implies," "should," "could" and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.
https://news.cision.com/scibase/r/today-is-the-first-day-of-the-subscription-period-in-scibase-rights-issue,c3965143
https://mb.cision.com/Main/12371/3965143/2748496.pdf
(c) 2024 Cision. All rights reserved., source